Diskussionsleiter: T. Eschenhagen (Hamburg), C. Maack (Würzburg)
| (P844) | Phosphatase nuclear targeting subunit PNUTS in inflammatory cardiomyopathy | |
| V. Zirkenbach, R. Öttl, R. Ignatz, M. Kaya, N. Frey, O. J. Müller, Z. Kaya (Heidelberg, Kiel) | ||
| (P845) | A novel approach based on genetic deconvolution of RNA-sequencing data identifies the molecular and cellular basis of antimiR-21 treatment in vivo. | |
| C. Beck, D. P. Ramanujam, A. P. Schön, S. Engelhardt (München) | ||
| (P846) | Phosphate promotes the cardiotoxicity of FGF23 | |
| M. Leifheit-Nestler, M. Bariani, F. Eitner, M. A. Wagner, I. Vogt, K. Zimmer, S. Hille, T. Thum, O. J. Müller, D. Haffner (Hannover, Kiel) | ||
| (P847) | Parvovirus B19 NS1 and VP1/2 mRNA expression indicates viral activity in endomyocardial biopsy-based diagnosis of patients with unexplained heart failure | |
| H. Pietsch, F. Escher, G. Aleshcheva, C. Baumeier, C.-T. Bock, H.-P. Schultheiss (Berlin) | ||
| (P848) | Human hypertrophic cardiomyopathy is associated with sarcomeric protein hypophosphorylation and oxidation. | |
| R. Hassoun, H. Budde, P. Steinwascher, M. Herwig, M. Tangos, D. Kolijn, Á. Kovács, A. Mügge, K. Jaquet, N. Hamdani, for the study group: AG13 (Bochum) | ||
| (P849) | Cardiac infection with SARS-CoV-2 in autopsy cases – 3’mRNA sequencing data | |
| D. Lindner, H. Bräuninger, B. Stoffers, G. Aleshcheva, M. Schweizer, J. Weimann, A. Fitzek, C. Edler, F. Escher, P. Kirchhof, H.-P. Schultheiss, S. Blankenberg, K. Püschel, D. Westermann (Hamburg, Berlin) | ||
| (P850) | Direct interaction of myosin binding protein C and troponin, which alters function and thin filament integrity by cTn mutants | |
| H. Budde, A. Al Haj, S. Fujita-Becker, A. Kostareva, R. Hassoun, M. M. Nowaczyk, A. Mügge, R. R. Schröder, H. G. Mannherz, K. Jaquet, D. Cimiotti (Bochum, Heidelberg, 44801; St. Petersburg, RU) | ||
| (P851) | Cardiac myocyte specific knockout of fibroblast growth factor 23 does not protect against high-pressure induced cardiac hypertrophy | |
| F. Eitner, S. Schwänen, M. Szaroszyk, K. Zimmer, T. Thum, J. Heineke, D. Haffner, M. Leifheit-Nestler (Hannover, Mannheim) | ||
| (P852) | SARS-CoV-2 induced production of Prostaglandin E2 impairing the immune response in COVID-19 disease | |
| M. Ricke-Hoch, E. Stelling, L. Lasswitz, A. Gunesch, F. Zapatero-Belinchon, G. Brogden, G. Gerold, T. Pietschmann, V. Montiel, J.-L. Balligand, T. Illig, F. Facciotti, E. Hirsch, A. Höfer, M. P. Kühnel, D. Jonigk, J. Eigendorf, U. Tegtbur, L. Mink, T. Pfeffer, A. Hilfiker, A. Haverich, D. Hilfiker-Kleiner (Hannover; Woluwé-Saint-Lambert, BE; Milan, Torino, IT) | ||
| (P853) | Urinary NT-proBNP: associated with progression of chronic kidney disease in ICD patients | |
| R. Allgaier, C. Strack, S. Wallner, U. Hubauer, E. Ücer, P. Lehn, A. Keyser, A. Luchner, L. S. Maier, C. G. Jungbauer (Regensburg) | ||
| (P854) | Diagnostic value of the modified Duke criteria in suspected infective endocarditis – the PRO-ENDOCARDITIS study | |
| I. Mahmoud, I. Dykun, M. Totzeck, C. Rischpler, A. Ruhparwar, K. Herrmann, T. Rassaf, A.-A. Mahabadi (Essen) |